- Home
- TSHA vs TXO Comparison
TSHA vs TXO Comparison
Compare TSHA & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TXO
- Stock Information
- Founded
- TSHA 2019
- TXO 2012
- Country
- TSHA United States
- TXO United States
- Employees
- TSHA N/A
- TXO N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- TSHA Health Care
- TXO Energy
- Exchange
- TSHA Nasdaq
- TXO Nasdaq
- Market Cap
- TSHA 728.4M
- TXO 788.9M
- IPO Year
- TSHA 2020
- TXO 2023
- Fundamental
- Price
- TSHA $3.36
- TXO $13.55
- Analyst Decision
- TSHA Strong Buy
- TXO Strong Buy
- Analyst Count
- TSHA 7
- TXO 2
- Target Price
- TSHA $8.71
- TXO $22.50
- AVG Volume (30 Days)
- TSHA 3.5M
- TXO 208.7K
- Earning Date
- TSHA 08-12-2025
- TXO 11-04-2025
- Dividend Yield
- TSHA N/A
- TXO 17.76%
- EPS Growth
- TSHA N/A
- TXO N/A
- EPS
- TSHA N/A
- TXO 0.30
- Revenue
- TSHA $8,098,000.00
- TXO $332,267,000.00
- Revenue This Year
- TSHA N/A
- TXO $31.08
- Revenue Next Year
- TSHA N/A
- TXO $11.32
- P/E Ratio
- TSHA N/A
- TXO $45.64
- Revenue Growth
- TSHA N/A
- TXO 15.94
- 52 Week Low
- TSHA $1.05
- TXO $13.35
- 52 Week High
- TSHA $3.40
- TXO $20.70
- Technical
- Relative Strength Index (RSI)
- TSHA 70.13
- TXO 31.96
- Support Level
- TSHA $2.79
- TXO $13.69
- Resistance Level
- TSHA $2.99
- TXO $14.15
- Average True Range (ATR)
- TSHA 0.16
- TXO 0.28
- MACD
- TSHA 0.03
- TXO -0.00
- Stochastic Oscillator
- TSHA 93.71
- TXO 22.94
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.